Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2013

Open Access 01-12-2013 | Research

Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma – benchmark for a prospective multi-institutional study

Authors: Takahisa Eriguchi, Atsuya Takeda, Yohei Oku, Satoshi Ishikura, Tomoki Kimura, Shuichi Ozawa, Takeo Nakashima, Yukinori Matsuo, Mitsuhiro Nakamura, Yasuo Matsumoto, Sadanori Yamazaki, Naoko Sanuki, Yoshinori Ito

Published in: Radiation Oncology | Issue 1/2013

Login to get access

Abstract

Introduction

Several single institution phase I and phase II trials of stereotactic ablative body radiotherapy (SABR) for liver tumors have reported promising results and high local control rates of over 90%. However, there are wide variations in dose and fractionation due to different prescription policies and treatment methods across SABR series that have been published to date.
This study aims to assess and minimize inter-institutional variations in treatment planning using SABR for hepatocellular carcinoma (HCC) in preparation for a prospective multi-institutional study.

Methods

Four institutions (A-D) participated in this study. Each institution was provided with data from four cases, including planning and diagnostic CT images and clinical information, and asked to implement three plans (a practice plan and protocol plans 1 and 2). Practice plans were established based on the current treatment protocols at each institution. In protocol plan 1, each institution was instructed to prescribe 40 Gy in five fractions within 95% of the planning target volume (PTV). After protocol plan 1 was evaluated, we made protocol plan 2, The additional regulation to protocol plan 1 was that 40 Gy in five fractions was prescribed to a 70% isodose line of the global maximum dose within the PTV. Planning methods and dose volume histograms (DVHs) including the median PTV D50 (Dm50) and the median normal liver volume that received 20 Gy or higher (Vm20) were compared.

Results

In the practice plan, Dm50 was 48.4 Gy (range, 43.6-51.2 Gy). Vm20 was 15.9% (range, 12.2-18.9%). In protocol plan 1, the Dm50 at institution A was higher (51.2 Gy) than the other institutions (42.0-42.2 Gy) due to differences in dose specifications. In protocol plan 2, variations in DVHs were reduced. The Dm50 was 51.9 Gy (range, 51.0-53.1 Gy), and the Vm20 was 12.3% (range, 10.4-13.2%). The homogeneity index was nearly equivalent at all institutions.

Conclusions

There were notable inter-institutional differences in practice planning using SABR to treat HCC. The range of PTV and normal liver DVH values was reduced when the dose was prescribed to an isodose line within the PTV. In multi-institutional studies, detailed dose specifications based on collaboration are necessary.
Appendix
Available only for authorised users
Literature
1.
Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md) 2011, 53: 1020-1022. 10.1002/hep.24199CrossRef
2.
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012, 56: 908-943.CrossRef
3.
Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, Levendag PC: Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta oncologica (Stockholm, Sweden) 2006, 45: 831-837. 10.1080/02841860600897934CrossRef
4.
Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol J Am Soc Clin Oncol 2008, 26: 657-664. 10.1200/JCO.2007.14.3529CrossRef
5.
Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, Cummings B, Ringash J, Tse RV, Knox JJ, Dawson LA: Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol J Am Soc Clin Oncol 2009, 27: 1585-1591. 10.1200/JCO.2008.20.0600CrossRef
6.
Cardenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone PA: Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Trans Oncol Pub Feder Spanish Oncol Soc Nat Cancer Ins Mexico 2010, 12: 218-225.
7.
Louis C, Dewas S, Mirabel X, Lacornerie T, Adenis A, Bonodeau F, Lartigau E: Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat 2010, 9: 479-487.CrossRefPubMed
8.
Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW: Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010, 10: 475. 10.1186/1471-2407-10-475CrossRefPubMedPubMedCentral
9.
Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR: Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiation Oncol, Biol, Physics 2011, 81: e447-e453. 10.1016/j.ijrobp.2011.04.011CrossRef
10.
van’t Riet A, Mak AC, Moerland MA, Elders LH, van der Zee W: A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. Int J Rad Oncol, Biol, Physics 1997, 37: 731-736. 10.1016/S0360-3016(96)00601-3CrossRef
11.
Fairchild A, Bar-Deroma R, Collette L, Haustermans K, Hurkmans C, Lacombe D, Maingon P, Poortmans P, Tomsej M, Weber DC, Gregoire V: Development of clinical trial protocols involving advanced radiation therapy techniques: the European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach. European J Cancer (Oxford, England : 1990) 2012, 48: 1048-1054. 10.1016/j.ejca.2012.02.008CrossRef
12.
Matsuo Y, Takayama K, Nagata Y, Kunieda E, Tateoka K, Ishizuka N, Mizowaki T, Norihisa Y, Sakamoto M, Narita Y: Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. Int J Rad Oncol, Biol, Physics 2007, 68: 416-425. 10.1016/j.ijrobp.2006.12.012CrossRef
13.
Bowden P, Fisher R, Mac Manus M, Wirth A, Duchesne G, Millward M, McKenzie A, Andrews J, Ball D: Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Rad Oncol, Biol, Physics 2002, 53: 566-573. 10.1016/S0360-3016(02)02783-9CrossRef
14.
Senan S, Van Sornsen De Koste J, Samson M, Tankink H, Jansen P, Nowak PJ, Krol AD, Schmitz P, Lagerwaard FJ: Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer. Radiotherapy Oncol J European Soc Therapeutic Radiol Oncol 1999, 53: 247-255. 10.1016/S0167-8140(99)00143-7CrossRef
15.
Nagata Y, Matsuo Y, Takayama K, Norihisa Y, Mizowaki T, Mitsumori M, Shibuya K, Yano S, Narita Y, Hiraoka M: Current status of stereotactic body radiotherapy for lung cancer. Int J Clin Oncol/Japan Soc Clin Oncol 2007, 12: 3-7. 10.1007/s10147-006-0646-6CrossRef
16.
Hurkmans CW, Cuijpers JP, Lagerwaard FJ, Widder J, van der Heide UA, Schuring D, Senan S: Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiation Oncol (London, England) 2009, 4: 1. 10.1186/1748-717X-4-1CrossRef
17.
ICRU Journal of ICRU. In Report 50: Prescribing, recording and reporting photon beam therapy. United Kingdom: Oxford University Press; 1993.
18.
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L: Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010, 37: 4078-4101. 10.1118/1.3438081CrossRefPubMed
19.
Oku Y, Takeda A, Kunieda E, Sudo Y, Oooka Y, Aoki Y, Shimouchi Y, Nishina R, Nomura K, Sugiura M, Ohashi T: Analysis of suitable prescribed isodose line fitting to planning target volume in stereotactic body radiotherapy using dynamic conformal multiple arc therapy. Practical Radiation Oncol 2012, 2: 46-53. 10.1016/j.prro.2011.06.001CrossRef
20.
Widder J, Hollander M, Ubbels JF, Bolt RA, Langendijk JA: Optimizing dose prescription in stereotactic body radiotherapy for lung tumours using Monte Carlo dose calculation. Radiotherapy Oncol J European Soc Therapeutic Radiol Oncol 2010, 94: 42-46. 10.1016/j.radonc.2009.11.008CrossRef
21.
Weber DC, Tomsej M, Melidis C, Hurkmans CW: QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. Radiotherapy Oncol J European Soc Therapeutic Radiol Oncol 2012, 105: 4-8. 10.1016/j.radonc.2012.08.008CrossRef
22.
Ohri N, Shen X, Dicker AP, Doyle LA, Harrison AS, Showalter TN: Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of Cooperative Group Clinical Trials. J Nat Cancer Ins 2013, 105: 387-393. 10.1093/jnci/djt001CrossRef
23.
Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran WJ Jr, Dignam J, Efstathiou JA, FitzGerald TJ, Hurkmans C: Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials–report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiation Oncol, Biol, Physics 2012, 83: 782-790.CrossRef
Metadata
Title
Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma – benchmark for a prospective multi-institutional study
Authors
Takahisa Eriguchi
Atsuya Takeda
Yohei Oku
Satoshi Ishikura
Tomoki Kimura
Shuichi Ozawa
Takeo Nakashima
Yukinori Matsuo
Mitsuhiro Nakamura
Yasuo Matsumoto
Sadanori Yamazaki
Naoko Sanuki
Yoshinori Ito
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2013
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-8-113

Other articles of this Issue 1/2013

Radiation Oncology 1/2013 Go to the issue

Research

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme

Research

Development and validation of automatic tools for interactive recurrence analysis in radiation therapy: optimization of treatment algorithms for locally advanced pancreatic cancer

Research

Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters

Research

Livin expression is an independent factor in rectal cancer patients with or without preoperative radiotherapy

Research

Preoperative chemoradiotherapy for locally advanced gastric cancer

Research

The influence of MRI scan position on patients with oropharyngeal cancer undergoing radical radiotherapy